Published in Gene Therapy Weekly, December 14th, 2006
"Our attendance at these conventions reinforces our belief in the sizable potential market for DNAPrint's proprietary DNA products," stated Richard Gabriel, DNAPrint president and chief executive officer. "We continue to invest in these activities because they generate sales and positive leads for future sales. In addition, these meetings allow us to forge valuable,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.